Biomednewsbreaks CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin Amid Strong Financial Position ...

Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 ...

Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReS ...

Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very ...

Presented positive ReSPECT-GBM Phase 1/2 Trial update data at the 2024 Congress of Neurological Surgeons Annual Conference, ...

INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) reported third quarter 2024 financial results and achievements on November 12th. Activity since the second quarter update was ...

Two sisters who lost their dad to an incurable brain tumour, along with their mother, have dedicated two days of research in ...

Cooperative housing societies (CHS/Society) often encounter unique legal and procedural challenges when managing shared ...

The Supreme Court on Wednesday sought the production of a video recording from the Delhi High Court Bar Association (DHCBA) ...

A new study identifies key genetic vulnerabilities in glioblastoma stem cells, revealing subtype-specific dependencies that ...

Waterman is backing the charity’s calls to increase national investment in brain tumour research to £35 million per year.

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...